Physician profile
Adrian Meyer
NPI 1639176787
$1,897.46
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $314.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $534.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $288.13 | 2019-2020 | |
| Novo Nordisk INC | $189.04 | 2019-2020 | |
| Amgen INC. | $132.07 | 2019-2020 | |
| Amarin Pharma, INC. | $80.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $79.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.12 | 2019 | |
| Allergan, INC. | $66.39 | 2019-2020 | |
| Melinta Therapeutics, LLC | $65.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $52.54 | 2019-2020 | |
| Pfizer INC. | $52.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38.64 | 2019 | |
| Abbvie INC. | $27.72 | 2019 | |
| Lilly USA, LLC | $26.93 | 2019-2020 | |
| Astellas Pharma US INC | $24.06 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $17.82 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $16.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.78 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $15.71 | 2019 | |
| Radius Health, INC. | $14.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.33 | 2019 | |
| Vivus LLC | $13.14 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.85 | 2019 | |
| Currax Pharmaceuticals LLC | $12.22 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.36 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.